Lakefront Biotherapeutics NV
LKFT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001421876
No open-market purchases or sales by Lakefront Biotherapeutics NV insiders were filed in the last 90 days; 76 institutions reported holding it in 13F filings for Q2 2026, worth $960.3M in total; Greenlight Capital is the only superinvestor holding it.
Other share classesGLPGF
Q2 2022 vs. Q1 2022
How the institutions holding Lakefront Biotherapeutics NV changed between Q1 2022 and Q2 2022.
All holders in Q2 2022All holders in Q1 2022
| Measure | Q1 2022 | Of which not filed for Q2 2022 | Q2 2022 | Change |
|---|---|---|---|---|
| Holders | 90 | 1 | 82 | −7 |
| Shares | 12.8M | 13.7K | 12.9M | +90.3K (+0.7%) |
| Value | $795.8M | $847.0K | $720.0M | −$75.0M (−9.4%) |
1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (12)
Institutions that held Lakefront Biotherapeutics NV at the end of Q2 2022 but not at the end of Q1 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jennison Associates LLC | 302,250 | $16.9M | 0.02% |
| Finepoint Capital LP | 259,400 | $14.5M | 5.00% |
| Alliancebernstein L.P. | 63,885 | $3.56M | 0.00% |
| Old Mission Capital LLC | 24,076 | $1.34M | 0.04% |
| SG Americas Securities, LLC | 14,858 | $829.0K | 0.01% |
| Credit Suisse AG | 13,135 | $733.0K | 0.00% |
| BNP Paribas Arbitrage, SA | 5,369 | $299.6K | 0.00% |
| Voloridge Investment Management, LLC | 4,159 | $232.0K | 0.00% |
| FNY Investment Advisers, LLC | 3,000 | $167.0K | 0.12% |
| International Biotechnology Trust PLC | 6,876 | $123.3K | 2.44% |
| State of Wyoming | 83 | $5.00K | 0.00% |
| Sargent Bickham Lagudis LLC | 30 | $2.00K | 0.00% |
Sold out (19)
Institutions that held Lakefront Biotherapeutics NV at the end of Q1 2022 and filed for Q2 2022 without it.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| BVF Inc | 1,046,283 | $64.9M |
| Point72 Asset Management, L.P. | 509,800 | $31.6M |
| Avidity Partners Management LP | 215,000 | $13.3M |
| OrbiMed Advisors LLC | 208,225 | $12.9M |
| Bridger Management, LLC | 153,700 | $9.53M |
| Sio Capital Management, LLC | 146,696 | $9.10M |
| Schonfeld Strategic Advisors LLC | 51,082 | $3.17M |
| Silverarc Capital Management, LLC | 41,002 | $2.54M |
| Arrowstreet Capital, Limited Partnership | 31,986 | $1.98M |
| Bluefin Capital Management, LLC | 30,273 | $1.88M |
| Barclays PLC | 19,772 | $1.23M |
| Monaco Asset Management SAM | 17,000 | $1.05M |
| Susquehanna International Group, LLP | 13,013 | $807.0K |
| Two Sigma Advisers, LP | 7,800 | $484.0K |
| State Street Corp | 3,898 | $242.0K |
| Simplex Trading, LLC | 1,994 | $123.0K |
| Acadian Asset Management LLC | 412 | $25.0K |
| Atlas Capital Advisors LLC | 348 | $21.6K |
| Money Concepts Capital Corp | 2 | $0 |
Not filed for Q2 2022 yet (1)
Institutions that held Lakefront Biotherapeutics NV at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q1 2022 | Value, Q1 2022 |
|---|---|---|
| Parametric Portfolio Associates LLC | 13,664 | $847.0K |